Curcumin Harmine Isovanillin Cancer Stem Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, often result in significant adverse side effects and are ineffective against cancer stem cells, leading to recurrence and drug resistance, due to their ability to resist chemotherapy and radiation therapy.
Innovation Solution
The use of novel combinations of curcumin, harmine, and isovanillin components in chemotherapeutic compositions that target cancer stem cells, minimizing side effects and enhancing treatment efficacy across various cancer types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat cancer, then tumor cells are killed, but cancer stem cells resist treatment leading to recurrence and drug resistance
Solution Approach 1:
The patent segments the cancer cell population by specifically targeting cancer stem cells (CSCs) as a distinct subset from differentiated tumor cells. The composition is designed to penetrate and act specifically on CSCs through mechanisms like P-gp inhibition and direct CSC-targeting compounds, separating the treatment approach from conventional bulk chemotherapy.
Solution Approach 2:
The patent changes the chemical and biological parameters of the treatment by using a multi-component composition with specific compounds (curcumin, harmine, isovanillin) that alter the pharmacological profile. This includes modifying drug permeability, inhibiting efflux pumps, and changing the biological activity to specifically target CSC markers and pathways.
2Productivity
If conventional chemotherapy is used to treat cancer, then some tumor cells are killed, but significant adverse side effects occur
Solution Approach 1:
The patent applies local quality by making the treatment selectively active against cancer stem cells while sparing normal cells. The composition achieves this through selective penetration into CSCs, specific binding to CSC markers, and localized inhibition of CSC-specific pathways, creating a differentiated treatment effect between cancer and normal tissues.
Solution Approach 2:
The patent uses intermediary compounds that facilitate selective delivery and action. Compounds like curcumin and harmine act as mediators that enhance penetration into CSCs, inhibit efflux pumps to trap therapeutic agents within CSCs, and modulate CSC-specific signaling pathways, thereby improving effectiveness while reducing off-target effects.
3Speed
If traditional chemotherapeutic agents are used, then rapid cell division is targeted, but cancer stem cells with slow turnover resist treatment
Solution Approach 1:
The patent inverts the conventional approach by not targeting rapidly dividing cells, but instead specifically targeting slow-turnover cancer stem cells. The composition is designed to penetrate quiescent and slowly dividing CSCs through mechanisms that bypass the need for active cell division, such as direct membrane penetration and P-gp inhibition.
Solution Approach 2:
The patent applies preliminary action by using compounds that prepare and sensitize cancer stem cells to treatment before the main therapeutic effect occurs. The composition includes agents that disrupt CSC protective mechanisms, inhibit efflux pumps in advance, and modulate signaling pathways to make CSCs vulnerable to subsequent therapeutic action.
Data Source
AI summary
Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.